ABSTRACT
It is estimated that around 10% of reproductive-age women of European ancestry, and 15% of women of Asian
ancestry are impacted by endometriosis. In endometriosis, glandular epithelium and stroma closely resembling
the cells of the endometrium grow outside of the uterine cavity, evading the typical cell-intrinsic (programmed
cell death) and cell-extrinsic safeguards (such as immune surveillance) that should prevent cells from surviving
at ectopic locations. Endometriosis causes myriad symptoms including infertility, dysmenorrhea (menstrual
cramps), deep dyspareunia (pain with deep penetration during sexual activity), dyschezia and dysuria (painful
bowel movements and voiding), and chronic pelvic pain. Epidemiologic and genetic studies consistently find
associations between endometriosis and inflammatory conditions such as asthma, irritable bowel syndrome
and autoimmune disorders. Inflammation plays a central role in endometriosis, and the overarching hypothesis
of this research is that studying risk loci shared by endometriosis and inflammatory conditions likely have a role
for hormonal modulation, since endometriosis is an estrogen-driven disease.
The goal of this proposal is to characterize key immune pathways that interact with hormonal responses in
endometriosis. This will be achieved through large-scale population based genetic comorbidity studies and
single cell systems biology methods to nominate shared risk genes and state-of-the-art single cell and spatial
molecular profiling of follicular and luteal phase endometriosis. Key cell-cell signaling axes will be validated for
their therapeutic potential using heterotypic in vitro and in vivo models of endometriosis. We will primarily focus
on the proinflammatory IL1 pathway as a risk locus for endometriosis coincides with the IL1 gene family
cluster. Based on integration of genome-wide risk data and single cell gene expression analysis of
endometriosis we hypothesize that IL1A and/or IL1B expression by M2 macrophages combined with IL1
receptor expression in hormone-sensitive endometriosis epithelial cells is the pathway underlying risk at this
locus. We will validate this hypothesis with multiomics and spatial profiling, and then dissect the roles of the
key genes and cell populations using our existing state-of-the-art in vitro and in vivo models.
This research will validate IL1 signaling as a key therapeutic target for endometriosis-associated inflammation,
and will likely nominate additional candidates. Subsequent research will focus on clinical translation of these
results. Endometriosis represents the ideal system to study hormonal regulation of inflammation, and
pleiotropy, and so we expect that the impact of this study will extend to other inflammatory traits that are more
common in women, and to the post-GWAS field in general.